ReleaseWire

The Global Infectious Vaccines Partnering Terms and Agreements 2010 to 2016: Deal trends, players and financials report provides a detailed understanding and analysis of how and why companies enter infectious vaccines partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

This report provides all the information you require to better understand Sun Pharmaceutical and its partnering interests and activities since 2010.

GlobalData's clinical trial report, "Acute Respiratory Distress Syndrome Global Clinical Trials Review, H1, 2016" provides an overview of Acute Respiratory Distress Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Respiratory Distress Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The metabolism of drugs in the body is generally carried out under the catalytic action of the enzyme. P450 enzyme in live is the mainly enzyme involved in drug pharmacokinetics in the body. The most important characteristic of P450 enzyme is that it can be induced or inhibited. At the same time, there are significant differences in race, age and sex, and the P450 enzyme has obvious polymorphism. Those effects will affect the content and activity of the enzyme so as to make the effect on the drug efficiency and the pharmacokinetics behavior. The following are the main factors that influence the pharmacokinetics of the drug:

Premier Biomedical, Inc. (OTCQB:BIEI) revealed the results of its latest cancer immunotherapy work being conducted by its research partner, UTEP, at the recent American Association for Cancer Research (AACR) Conference, in New Orleans. The patent-pending anti-cancer antibody is intended to compete in the immunotherapy segment of the $100 plus billion cancer treatment market, with drugs like Yervoy® by Bristol Meyers Squibb who is projecting sales of $14 billion by 2018.

ABC Pharmacy of Beverly Hills, a premier pharmacy in Beverly Hills, has announced that it is now offering free delivery to the residents of Beverly Hills. This announcement came in the wake of the realization that there was a lack in the industry for premier pharmacies that deliver. The pharmacy in Beverly Hills was quick to add this offering to their list of features so as to continue their dedication to customer service.

ABC Compounding Pharmacy is a premier Long Beach compounding pharmacy that is now offering its top-ranked services to the southern California community at large. The brand's decision to offer their services to southern California came after the realization that there was a lack of high-quality compounding pharmacies in the Los Angeles.

Fast Market Research announces the availability of the new Current Partnering report, "Global Gastric Cancer Partnering 2010 to 2016", on their comprehensive research portal

Pluristem Therapeutics Inc, a leading developer of placenta-derived cell therapy products, today announced that it has entered into a licensing agreement with TES Holdings Co., Ltd., a venture company derived from the University of Tokyo, to obtain a key patent in Japan to cover the treatment of ischemic diseases with placental cell therapy rounding out the Company's IP coverage. This license follows Pluristem's recent announcement that the Japan Patent Office granted the Company two key patents addressing three-dimensional methods for expanding placental and adipose cells, and specified cell therapies produced from placental tissue using these methods.

Critical Care, Pulmonary and Sleep Associates, sleep specialist doctors in Denver, are now offering an effective treatment for all sleep disorders including sleep apnea, narcolepsy and restless leg syndrome. They have a team of physicians and other knowledgeable health care professionals who have immense knowledge and deep understanding of sleep disorders. They screen their patients with a thorough history and physical examination to determine risk factors. To conduct sleep analysis on recommended patients, they have set up a highly advanced sleep lab. Patients seeking a reputable and reliable healthcare center to help them with a cure for their sleep disorders can count on them for providing them with effective treatments.

Creative Biostructure, a world leading biotech company specialized in providing contract services to both academia and biotech/pharmaceutical industries in the field of structural biology, has launched high-throughput and high-quality UniCrysTM crystallization services by using state-of-the-art facilities and technologies in the field of X-ray Crystallography, aiming to help its customers accelerate the research progress.

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a company note on Innovus Pharmaceuticals, Inc. (OTCBB:INNV)

Based in Newport Beach, California, American Pharmacy Purchasing Alliance (APPA) recently inaugurated their Industry Awards and the winners have now been published on their official website. APPA is a community of dedicated members that is working towards the advancement of the pharmaceutical purchasing industry. According the company website, the pharmaceutical purchasing industry is still "undervalued" and needs dedicated individuals who can work as a team to further the industry.

Actinium Pharmaceuticals, Inc.("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company has entered into an agreement with Zevacor Pharma, Inc. (formerly IBA Molecular North America, Inc.) for the clinical production and supply of Iomab-B for the upcoming pivotal Phase 3 SIERRA trial. Pursuant to the agreement, Zevacor Pharma, Inc. will perform the Good Manufacturing Practices (GMP) manufacturing, testing, releasing and distribution of Iomab-B for Actinium's pivotal Phase 3 SIERRA trial. Iomab-B is a radioimmunotherapy intended to be an induction and conditioning agent prior to a bone marrow transplant for Acute Myeloid Leukemia (AML) patients over the age of 55. Actinium's Iomab-B has received orphan drug designation from the U.S. Food and Drug Administration (FDA) and the pivotal Phase 3 SIERRA trial is expected to enroll 150 patients.

Bryant Brown Healthcare, a leading independent medical advertising agency, has voiced its opposition to a congressional bill calling for a three-year moratorium on advertising newly approved prescription drugs directly to consumers.

There exist vast opportunities for prescription drugs in the constipation market. However, OTC drugs and laxatives are generally used for treating constipation, patients and physicians have started recognizing the importance of branded drugs. Future growth of the constipation market is based on continued growth of prescription therapies to treat constipation, increased research and development of novel drugs by biopharmaceutical companies, increasing patient and physician awareness of effective prescription alternatives to Over-the-Counter medications.

Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or the "Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that the Company will host a webinar to discuss the SIERRA trial, the Company's upcoming pivotal Phase 3 clinical trial for Iomab-B. The webinar will provide an overview of the use of hematopoietic stem cell transplant (HSCT), known as a bone marrow transplant (BMT) in relapsed or refractory Acute Myeloid Leukemia (AML) patients over the age of 55, an introduction to the SIERRA trial and anticipated timelines and milestones for the trial. Participant information for the webinar is as follows:

GlobalData's clinical trial report, "Reperfusion Injury Global Clinical Trials Review, H1, 2016" provides an overview of Reperfusion Injury clinical trials scenario. This report provides top line data relating to the clinical trials on Reperfusion Injury. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GlobalData's clinical trial report, "Neuroendocrine Carcinoma Global Clinical Trials Review, H1, 2016" provides an overview of Neuroendocrine Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Neuroendocrine Carcinoma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GlobalData's clinical trial report, "Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2016" provides an overview of Acid Indigestion / Heartburn/ Pyrosis clinical trials scenario. This report provides top line data relating to the clinical trials on Acid Indigestion / Heartburn/ Pyrosis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GlobalData's clinical trial report, "Cancer Cachexia Global Clinical Trials Review, H1, 2016" provides an overview of Cancer Cachexia clinical trials scenario. This report provides top line data relating to the clinical trials on Cancer Cachexia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

GlobalData's clinical trial report, "Inguinal Hernia Global Clinical Trials Review, H1, 2016" provides an overview of Inguinal Hernia clinical trials scenario. This report provides top line data relating to the clinical trials on Inguinal Hernia. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

Profacgen, a world leading biotech company that offers a full range of biopharmaceutical development and bio-manufacturing services that cover strategic consultancy, world-class process development, cGMP manufacturing, and analytical development, announced the launch of Co-Immunoprecipitation service, aiming to provide its customers the latest techniques.

Recent developments have shown that there are a lot of off-label prescription scandal when it comes to the use of Zofran during the time of pregnancy by expectant mothers. Manufactured by the Glaxo Smith Kline (GSK), it is an antiemetic medication.

Author Blair Thielemier, PharmD knows from personal experience the career path you worked so hard to achieve may not always go as planned. Pharmacists are licensed to dispense medication and improve patient outcomes. They spend many years honing their skills through coursework and clinical experience. After years of working as a traditional clinical Pharmacist she was forced to make a sudden change. She bridged the gap between her training and Entrepreneurship to create new business model. She will launch her new book How to Build a Pharmacy Consulting Business: Your Rx for Finding Freedom and Loving your Career on 1 April 2016.